Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases

References

• AccordiniSCorsicoAGBraggionMThe cost of persistent asthma in Europe: an international population-based study in adultsInt Arch Allergy Immunol201316019310122948386
   PubMed Web of Science ®Google Scholar
• RabeKFAdachiMLaiCKWorldwide severity and control of asthma in children and adults: the global asthma insights and reality surveysJ Allergy Clin Immunol20041141404715241342
   PubMed Web of Science ®Google Scholar
• WenzelSSevere asthma: from characteristics to phenotypes to endotypesClin Exp Allergy201242565065822251060
   PubMed Web of Science ®Google Scholar
• ManuyakornWHowarthPHHolgateSTAirway remodelling in asthma and novel therapyAsian Pac J Allergy Immunol2013311310823517388
   PubMed Web of Science ®Google Scholar
• SchuijsMJWillartMAHammadHLambrechtBNCytokine targets in airway inflammation. Lung damage and airway remodelling in severe asthmaCurr Opin Pharmacol201313335136123643194
   PubMed Web of Science ®Google Scholar
• BrightlingCEGuptaSGonemSSiddiquiSLung damage and airway remodelling in severe asthmaClin Exp Allergy201242563864922192725
   PubMed Web of Science ®Google Scholar
• FahyJVEosinophilic and neutrophilic inflammation in asthma: insights from clinical studiesProc Am Thorac Soc200916325625919387026
   PubMedGoogle Scholar
• PepeCFoleySShannonJDifferences in airway remodeling between subjects with severe and moderate asthmaJ Allergy Clin Immunol200511654454916159622
   PubMed Web of Science ®Google Scholar
• HumbertMBeasleyRAyresJBenefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy200560330931615679715
   PubMed Web of Science ®Google Scholar
• NormansellRWalkerSMilanSJOmalizumab for asthma in adults and childrenCochrane Database Syst Rev20141CD00355924414989
   PubMed Web of Science ®Google Scholar
• ZhangJYWenzelSETissue and BAL based biomarkers in asthmaImmunol Allergy Clin North Am20072762363217996580
   PubMed Web of Science ®Google Scholar
• BousquetJChanezPLacosteJYEosinophilic inflammation in asthmaN Engl J Med1990323103310392215562
   PubMed Web of Science ®Google Scholar
• TurnerMOHussackPSearsMRExacerbations of asthma without sputum eosinophiliaThorax199550105710617491553
   PubMed Web of Science ®Google Scholar
• LeckieMJten BrinkeAKhanJEffects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic responseLancet20003562144214811191542
   PubMed Web of Science ®Google Scholar
• Flood-PagePTMenzies-GowANKayABRobinsonDSEosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airwayAm J Respir Crit Care Med2003167219920412406833
   PubMed Web of Science ®Google Scholar
• UhmTGKimBSChungIYEosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthmaAllergy Asthma Immunol Res201242687922379601
   PubMed Web of Science ®Google Scholar
• McKinnonMBankMSolariRRobinsonGInterleukin-5 and the interleukin receptor: targets for drug discovery in asthmaSandersonCJInterleukin-5: From molecule to Drug Target for AsthmaNew YorkMarcel Dekker, Inc1999299320
   Google Scholar
• Menzies-GowAFlood-PagePSehmiRAnti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmaticsJ Allergy Clin Immunol2003111471471912704348
   PubMed Web of Science ®Google Scholar
• WellsTNGraberPProudfootAEThe three-dimensional structure of human interleukin-5 at 2.4-angstroms resolution: implication for the structures of other cytokinesAnn N Y Acad Sci1994287251181278030983
   PubMed Web of Science ®Google Scholar
• TakatsuKNakajimaHIL-5 and eosinophiliaCurr Opin Immunol20082028829418511250
   PubMed Web of Science ®Google Scholar
• KouroTTakatsuKIL-5- and eosinophil-mediated inflammation: from discovery to therapyInt Immunol200921121303130919819937
   PubMed Web of Science ®Google Scholar
• TanakaHKomaiMNagaoKRole of interleukin-5 and eosinophils in allergen-induced airway remodeling in miceAm J Respir Cell Mol Biol2004316214975941
   PubMed Web of Science ®Google Scholar
• BecchettiEBaniDBaroniTIstologia UmanaNapoliIdelson-Gnocchi20113933949788879475419
   Google Scholar
• RosenbergHFDyerKDFosterPSEosinophils: changing perspectives in health and diseaseNat Rev Immunol201313192223154224
   PubMed Web of Science ®Google Scholar
• ValentPThe phenotype of human eosinophils, basophils, and mast cellsJ Allergy Clin Immunol199494117711837798557
   PubMed Web of Science ®Google Scholar
• TobaKKoikeTShibataANovel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophilsCytometry19993524925910082306
   PubMedGoogle Scholar
• DahinenCARihsSOchsensbergerBRegulation of cytokine expression by human blood basophilsInt Arch Allergy Immunol19971131341379130503
   PubMed Web of Science ®Google Scholar
• KowalKNolteHSkovPSEffect of allergen-specific immuno-therapy on recombinant human interleukin 3-mediated amplification of allergen-induced basophil histamine releaseAllergy Asthma Proc20052645646216541969
   PubMed Web of Science ®Google Scholar
• LloydCMRankinSMChemokines in allergic airway diseaseCurr Opin Pharmacol2003344344812901955
   PubMed Web of Science ®Google Scholar
• BochnerBSSiglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptorsClin Exp Allergy20093931732419178537
   PubMed Web of Science ®Google Scholar
• KvarnhammarAMCardellLOPattern recognition receptors in human eosinophilsImmunology2012136112022242941
   PubMed Web of Science ®Google Scholar
• MånssonACardellLORole of atopic status in Toll-like receptor (TLR)7- and TLR9-mediated activation of human eosinophilsJ Leukoc Biol20098571972719129482
   PubMed Web of Science ®Google Scholar
• NakagomeKMatsushitaSNagataMNeutrophilic inflammation in severe asthmaInt Arch Allergy Immunol201215819610222627375
   PubMed Web of Science ®Google Scholar
• BafadhelMMcCormickMSahaSProfiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary diseaseRespiration2012831364421912093
   PubMed Web of Science ®Google Scholar
• MenzellaFLusuardiMGaleoneCZucchiLTailored therapy for severe asthmaMultidiscip Respir Med2015101125671117
   PubMedGoogle Scholar
• Flood-PagePSwensonCFaifermanIA study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthmaAm J Respir Crit Care Med20071761062107117872493
   PubMed Web of Science ®Google Scholar
• HaldarPBrightlingCEHargadonBMepolizumab and exacerbations of refractory eosinophilic asthmaN Engl J Med200936097398419264686
   PubMed Web of Science ®Google Scholar
• NairPPizzichiniMMKjarsgaardMMepolizumab for prednisone-dependent asthma with sputum eosinophiliaN Engl J Med200936098599319264687
   PubMed Web of Science ®Google Scholar
• PavordIDKornSHowarthPMepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialLancet201238065165922901886
   PubMed Web of Science ®Google Scholar
• CastroMZangrilliJWechslerMEReslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsLancet Respir Med20153535536625736990
   PubMed Web of Science ®Google Scholar
• LimHFNairPEfficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthmaExpert Rev Respir Med20159213514225578680
   PubMed Web of Science ®Google Scholar
• Zia-AmirhosseiniPMinthornEBenincosaLJPharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeysJ Pharmacol Exp Ther199929131060106710565825
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyWithdrawal Assessment Report for BosatriaLondon, UKEuropean Medicines Agency2009 Doc. Ref: EMEA/454803/2009
   Google Scholar
• LopezAFSandersonCJGambleJRCampbellHDYoungIGVadasMARecombinant human interleukin 5 is a selective activator of human eosinophil functionJ Exp Med198816712192242826636
   PubMed Web of Science ®Google Scholar
• OhnishiTSurSCollinsDSFishJEGleichGJPetersSPEosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challengeJ Allergy Clin Immunol19939246076158409120
   PubMed Web of Science ®Google Scholar
• ClutterbuckEJSandersonCJRegulation of human eosinophil precursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6, and rh granulocyte- macrophage colony-stimulating factorBlood1990759177417792184902
   PubMed Web of Science ®Google Scholar
• HartTKCookRMZia-AmirhosseiniPPreclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeysJ Allergy Clin Immunol2001108225025711496242
   PubMed Web of Science ®Google Scholar
• WenzelSEEosinophils in asthma – closing the loop or opening the door?N Engl J Med2009360101026102819264692
   PubMed Web of Science ®Google Scholar
• SimpsonJLScottRBoyleMJGibsonPGInflammatory subtypes in asthma: assessment and identification using induced sputumRespirology200611546116423202
   PubMed Web of Science ®Google Scholar
• OrtegaHChuppGBardinPThe role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophiliaEur Respir J201444123924124659543
   PubMed Web of Science ®Google Scholar
• OrtegaHLiHSurukiRAlbersFGordonDYanceySCluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthmaAnn Am Thorac Soc20141171011101724983709
   PubMedGoogle Scholar
• PrazmaCMWenzelSBarnesNDouglassJAHartleyBFOrtegaHCharacterisation of an OCS-dependent severe asthma population treated with mepolizumabThorax201469121141114224834924
   PubMed Web of Science ®Google Scholar
• OrtegaHGLiuMCPavordIDMepolizumab treatment in patients with severe eosinophilic asthmaN Engl J Med2014371131198120725199059
   PubMed Web of Science ®Google Scholar
• HaldarPBrightlingCESingapuriAOutcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysisJ Allergy Clin Immunol2014133392192324418480
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineEfficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants with Severe Eosinophilic Asthma on Markers of Asthma Control2014 Available from: https://clinicaltrials.gov/ct2/show/NCT02281318Accessed June 1, 2015 NLM Identifier: NCT02281318
   Google Scholar
• LiuYZhangSLiDWJiangSJEfficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trialsPLoS One201383e5987223544105
   PubMed Web of Science ®Google Scholar
• NowakRMParkerJMSilvermanRAA randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthmaAm J Emerg Med2015331142025445859
   PubMed Web of Science ®Google Scholar
• GarrettJKJamesonSCThomsonBAnti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromesJ Allergy Clin Immunol2004113111511914699394
   PubMed Web of Science ®Google Scholar
• RothenbergMEKlionADRoufosseFEMepolizumab HES Study GroupTreatment of patients with the hypereosinophilic syndrome with mepolizumabN Engl J Med200820358(12)1215122818344568
   PubMed Web of Science ®Google Scholar
• LeifermanKMA role for eosinophils in atopic dermatitisJ Am Acad Dermatol2001451S21S2411423867
   PubMed Web of Science ®Google Scholar
• WediBRaapULewrickHKappADelayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitisJ Allergy Clin Immunol19971005365439338549
   PubMed Web of Science ®Google Scholar
• GnanakumaranGBabuKSTechnology evaluation: mepolizumab, GlaxoSmithKlineCurr Opin Mol Ther20035332132512870444
   PubMedGoogle Scholar
• OldhoffJMDarsowUWerfelTAnti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitisAllergy200560569369615813818
   PubMed Web of Science ®Google Scholar
• MoosigFGrossWLHerrmannKBremerJPHellmichBTargeting interleukin-5 in refractory and relapsing Churg–Strauss syndromeAnn Intern Med201115534134321893636
   PubMed Web of Science ®Google Scholar
• KimSMarigowdaGOrenEIsraelEWechslerMEMepolizumab as a steroid-sparing treatment option in patients with Churg–Strauss syndromeJ Allergy Clin Immunol201012561336134320513524
   PubMed Web of Science ®Google Scholar
• OtaniIMAnilkumarAANewburyROAnti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitisJ Allergy Clin Immunol201313161576158223623266
   PubMed Web of Science ®Google Scholar
• StraumannAConusSGrzonkaPAnti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trialGut201059213019828470
   PubMed Web of Science ®Google Scholar
• SpergelJMRothenbergMECollinsMHReslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trialJ Allergy Clin Immunol201212945646322206777
   PubMed Web of Science ®Google Scholar
• GevaertPVan BruaeneNCattaertTMepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposisJ Allergy Clin Immunol2011128598999521958585
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineEfficacy and Safety of Mepolizumab as an Add-On Treatment in Chronic Obstructive Pulmonary Disease (COPD)2014 Available from: https://clinicaltrials.gov/ct2/show/NCT02105961Accessed May 26, 2015 NLM Identifier: NCT02105961
   Google Scholar
• McMaster UniversityMepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) with Eosinophilic Bronchitis2011 Available from: https://clinicaltrials.gov/ct2/show/NCT01463644Accessed May 26, 2015 NLM Identifier: NCT01463644
   Google Scholar
• RoufosseFEKahnJEGleichGJLong-term safety of mepolizumab for the treatment of hypereosinophilic syndromesJ Allergy Clin Immunol2013131246146723040887
   PubMed Web of Science ®Google Scholar
• RobinsonDSMepolizumab treatment for asthmaExpert Opin Biol Ther201313229530222998420
   PubMed Web of Science ®Google Scholar
• KikuchiSNagataMKikuchiIHagiwaraKKanazawaMAssociation between neutrophilic and eosinophilic inflammation in patients with severe persistent asthmaInt Arch Allergy Immunol2005137171115947478
   PubMed Web of Science ®Google Scholar
• MenzellaFFacciolongoNPiroRClinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-upTher Adv Respir Dis201262879522323442
   PubMed Web of Science ®Google Scholar
• Cost a focus as GSK takes lead in new wave of biotech lung drugs Reuters Edition UK. Mon September 8, 2014 1:45 pm BST. Available from: http://uk.reuters.com/article/2014/09/08/health-respiratory-gsk-idUKL5N0R921Y20140908Accessed July 31, 2015
   Google Scholar